Section 1: Enzymatic DNA Fragmentation (Manually)
By onThis protocol details manual enzymatic DNA Fragmentation prior to Section 2: NGS library preparation for sequencing.
A549 PIP4P1 (TMEM55B) KO (CVCL_D3VW)
By onA549 PIP4P1 (TMEM55B) CRISPR/CAS9 A549 knock-out cell line generated from parental A549 cells (ATCC A549 CCl-185) using CRISPR/Cas9 gene-editing technology. The cell line was verified by immunoblotting analysis and DNA-sequencing analysis. Used in publication: doi: https://doi.org/10.1101/2023.06.07.544051
mRNA purification by translating ribosome affinity purification (TRAP) of DAT-expressing cells (dopaminergic neurons) in mouse ventral midbrain
By onThis protocol describes the capture of eGFP-L10a-tagged ribosomes and mRNA from DAT-expressing cells (dopaminergic neurons) in mouse ventral midbrain.
Immunocytochemistry for CASR in iPSc-derived dopaminergic neurons
By onCASR immunocytochemistry protocol to accompany Kilfeather, Khoo et al., 2023: Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease
KOLF2.1 iPSCs AAVS1-NGN2
By oniPSCs from British Caucasian male, modified with NEUROG2 using CRISPR/Cas9 in AAVS1 locus. Contains mutations in ARID2 (p.Pro197Hisfs*12) and COL3A1 (p.Gly1176Ser). Derived from skin fibroblasts of a 55-59-year-old male.
Whole mount dissection and staining of enteric nervous system
By onThis protocol details whole mount dissection and staining of the enteric nervous system.
Regional Mouse Brain Analysis (Modified QUINT)
By onThis is series of protocols that has been adapted from published and unpublished protocols broadly referred to as the QUINT workflow: QuPath visualization/segmentation QuickNII Brain Atlas Registration QMask Hemispheric Separation Visualign Transformation Nutil Data Integration QUINT Workflow Appendix QUINT Workflow for Fluorescence Note that the original QUINT workflow was generated by Yates and colleagues, and all credit for development of these programs goes to that team. References for each software are listed in the protocol.
Detection of accessible cholesterol in primary cilia using purified His-ALOD4-mNeon in 3T3 Fibroblasts
By onThe protocol described here is based upon previously established methods (Kinnebrew et al., 2019; Johnson and Radhakrishnan, 2021) and has also been used successfully to label cilia in RPE cells.
Section 3: Libraries quality control (QC)
By onThis protocol details quality control of libraries and should be performed after Section 2: NGS library preparation for sequencing.
Section 2: NGS library preparation for sequencing
By onThis protocol details NGS library preparation for sequencing and should be performed after Section 1: Enzymatic DNA Fragmentation (Manually).
Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms
By onZenodo archive contains post-sequence QC, taxonomic, and functional profiling data. Supplementary Code includes workflow and bioinformatic processing used in the manuscript. Raw sequences and metadata are on NCBI SRA under BioProject ID PRJNA834801.
HEK293::TMEM192-3xHA RB1CC1-/- mNEON-YIPF4
By onHEK293::TMEM192-3xHA RB1CC1-/- mNEON-YIPF4 PubMed=37757899; Characteristics: Using CRISPR/Cas9 TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope (from parent cell line). Characteristics: Using CRISPR/Cas9 YIPF4 was N-terminally tagged on both alleles with mNeonGreen (PubMed=37757899). Knockout cell: Method=CRISPR/Cas9; 15574; RB1CC1. Transfected with: UniProtKB; A0A1S4NYF2; mNeonGreen (derivative of Branchiostoma lanceolatum blFP-Y3). Transformant: NCBI_TaxID; 28285; Adenovirus 5. Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113. NCBI_TaxID=9606; ! Homo sapiens (Human) RRID:CVCL_D1KQ ! HEK293::TMEM192-3xHA RB1CC1-/- Female Fetus
HEK293::TMEM192-3xHA RB1CC1-/-
By onHEK293::TMEM192-3xHA RB1CC1-/- PubMed=37757899; Characteristics: Using CRISPR/Cas9 TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope (from parent cell line). Knockout cell: Method=CRISPR/Cas9; 15574; RB1CC1. Transformant: NCBI_TaxID; 28285; Adenovirus 5. Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113. NCBI_TaxID=9606; ! Homo sapiens (Human) RRID:CVCL_C0I5 ! HEK293::TMEM192-3xHA Female Fetus Transformed cell line
HeLa::TMEM192-3xHA
By onHeLa ::TMEM192-3xHA PubMed=37757899; Population: African American. Characteristics: Using CRISPR/Cas9 TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope (from parent cell line). Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18). Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002. NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma NCBI_TaxID=9606; ! Homo sapiens (Human) RRID:CVCL_0030 ! HeLa Female 30Y6M Cancer cell line
Gut mucosal cells transfer α-synuclein to the vagus nerve
By onPublished: These findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells. View original preprint.
Rethinking the network determinants of motor disability in Parkinson’s disease
By onFor roughly the last 30 years, the notion that striatal dopamine (DA) depletion was the critical determinant of network pathophysiology underlying the motor symptoms of Parkinson’s disease (PD) has dominated the field. While the basal ganglia circuit model underpinning this hypothesis has been of great heuristic value, the hypothesis itself has never been directly tested. Moreover, studies in the last couple of decades have made it clear that the network model underlying this hypothesis fails to incorporate key features of the basal ganglia, including the fact that DA acts throughout the basal ganglia, not just in the striatum. Underscoring this point, recent work using a progressive mouse model of PD has shown that striatal DA depletion alone is not sufficient to induce parkinsonism and that restoration of extra-striatal DA signaling attenuates parkinsonian motor deficits once they appear. Given the broad array of discoveries in the field, it is time for a new model of the network determinants of motor disability in PD.
Fast-scan cyclic voltammetry to assess dopamine release in ex vivo mouse brain slices
By onThis protocol is to assess whether a drug changes the dopamine concentration released following a single pulse (1p) electrical stimulation.
Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson’s Disease
By onPreprint: The present study investigates the impact of NDP-MSH, a synthetic melanocortin receptor (MCR) agonist that does not cross BBB, on the immune system and the nigrostriatal dopaminergic system in mouse model of PD.
Peripheral MC1R activation modulates immune responses and confers neuroprotection in a mouse model of Parkinson’s disease
By onDataset corresponding to the article, "Peripheral MC1R activation modulates immune responses and confers neuroprotection in a mouse model of Parkinson's disease."
Nigrostriatal Tau Pathology in parkinsonism and Parkinson’s disease
By onWhile Parkinson’s disease remains clinically defined by cardinal motor symptoms resulting from nigrostriatal degeneration, it is now appreciated that the disease commonly consists of multiple pathologies, but it is unclear where these co-pathologies occur early in disease and whether they are responsible for the nigrostriatal degeneration. For the past number of years, we have been studying a well-characterized cohort of subjects with motor impairment that we have termed mild motor deficits. Motor deficits were determined on a modified and validated Unified Parkinson’s Disease Rating Scale III but were insufficient in degree to diagnose Parkinson’s disease. However, in our past studies, cases in this cohort had a selection bias, as both a clinical syndrome in between no motor deficits and Parkinson’s disease, plus nigral Lewy pathology as defined post-mortem, were required for inclusion. Therefore, in the current study, we only based inclusion on the presence of a clinical phenotype with mild motor impairment insufficient to diagnose Parkinson’s disease. Then, we divided this group further based upon whether or not subjects had a synucleinopathy in the nigrostriatal system. Here we demonstrate that loss of nigral dopaminergic neurons, loss of putamenal dopaminergic innervation and loss of the tyrosine hydroxylase-phenotype in the substantia nigra and putamen occur equally in mild motor deficit groups with and without nigral alpha-synuclein aggregates. Indeed, the common feature of these two groups is that both have similar degrees of AT8 positive phosphorylated tau, a pathology not seen in the nigrostriatal system of age-matched controls. These findings were confirmed with early (tau Ser208 phosphorylation) and late (tau Ser396/ Ser404 phosphorylation) tau markers. This suggests that the initiation of nigrostriatal dopaminergic neurodegeneration occurs independently of alpha-synuclein aggregation and can be tau mediated.